Exact Mass: 706.3962

Exact Mass Matches: 706.3962

Found 79 metabolites which its exact mass value is equals to given mass value 706.3962, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Hovenidulcioside A2

3-(4b,8,8,10a-Tetramethyl-5-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-dodecahydro-2H-spiro[oxolane-3,1-phenanthrene]-2-yl)-1-(4-methyl-5-oxo-2,5-dihydrofuran-2-yl)butan-2-yl acetic acid

C38H58O12 (706.3928)


Hovenidulcioside A2 is a constituent of Hovenia dulcis (raisin tree). Constituent of Hovenia dulcis (raisin tree)

   

PA(12:0/6 keto-PGF1alpha)

[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-(dodecanoyloxy)propoxy]phosphonic acid

C35H63O12P (706.4057)


PA(12:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/6 keto-PGF1alpha), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(6 keto-PGF1alpha/12:0)

[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-(dodecanoyloxy)propoxy]phosphonic acid

C35H63O12P (706.4057)


PA(6 keto-PGF1alpha/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/12:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/TXB2)

[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-(dodecanoyloxy)propoxy]phosphonic acid

C35H63O12P (706.4057)


PA(12:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/TXB2), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(TXB2/12:0)

[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-(dodecanoyloxy)propoxy]phosphonic acid

C35H63O12P (706.4057)


PA(TXB2/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/12:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/6 keto-PGF1alpha)

[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O12P (706.4057)


PA(i-12:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/6 keto-PGF1alpha), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(6 keto-PGF1alpha/i-12:0)

[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O12P (706.4057)


PA(6 keto-PGF1alpha/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/i-12:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/TXB2)

[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O12P (706.4057)


PA(i-12:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/TXB2), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(TXB2/i-12:0)

[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O12P (706.4057)


PA(TXB2/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/i-12:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Hyalodendroside A

Hyalodendroside A

C38H58O12 (706.3928)


   

24-Demethylbafilomycin

24-Demethylbafilomycin

C38H58O12 (706.3928)


   

(2S,3R,4R,5R,6S)-2-{[(2S,3R,4S,5S)-4,5-dihydroxy-2-[(1S,2R,4S,7S,8R,9S,13R,14R,16S)-7,9,13-trimethyl-5-methylidene-5-oxaspiro[oxane-2,6-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18-en-14-oloxy]oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

(2S,3R,4R,5R,6S)-2-{[(2S,3R,4S,5S)-4,5-dihydroxy-2-[(1S,2R,4S,7S,8R,9S,13R,14R,16S)-7,9,13-trimethyl-5-methylidene-5-oxaspiro[oxane-2,6-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18-en-14-oloxy]oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C38H58O12 (706.3928)


   

DESGLUCORUSCIN

DESGLUCORUSCIN

C38H58O12 (706.3928)


   

periforoside I

periforoside I

C38H58O12 (706.3928)


   

3alpha-Angeloyloxy-2beta-hydroxy-ent-labd-7-en-15-oic acid-2-O-beta-fucopyranoside methyl ester triacetate

3alpha-Angeloyloxy-2beta-hydroxy-ent-labd-7-en-15-oic acid-2-O-beta-fucopyranoside methyl ester triacetate

C38H58O12 (706.3928)


   

2-O-malonyl-cimiaceroside

2-O-malonyl-cimiaceroside

C38H58O12 (706.3928)


   

25,30-dicarboxy-26,27,28,29-tetraacetoxy-10,11,14,15-tetrahydrosqualene

25,30-dicarboxy-26,27,28,29-tetraacetoxy-10,11,14,15-tetrahydrosqualene

C38H58O12 (706.3928)


   

3alpha-Angeloyloxy-2beta,15-dihydroxy-ent-labd-7-ene-2-O-beta-xylopyranoside tetraacetate

3alpha-Angeloyloxy-2beta,15-dihydroxy-ent-labd-7-ene-2-O-beta-xylopyranoside tetraacetate

C38H58O12 (706.3928)


   

Antibiotic PD 118576A3

Antibiotic PD 118576A3

C38H58O12 (706.3928)


   

Leu Arg Asp Leu Tyr

Leu Arg Asp Leu Tyr

C33H54N8O9 (706.4014)


   

C38H58O12_(1beta,3beta,9xi,14xi)-3-Hydroxyspirosta-5,25(27)-dien-1-yl 2-O-(6-deoxy-alpha-L-mannopyranosyl)-alpha-L-arabinopyranoside

NCGC00384498-01_C38H58O12_(1beta,3beta,9xi,14xi)-3-Hydroxyspirosta-5,25(27)-dien-1-yl 2-O-(6-deoxy-alpha-L-mannopyranosyl)-alpha-L-arabinopyranoside

C38H58O12 (706.3928)


   

Hovenidulcioside A2

3-(4b,8,8,10a-tetramethyl-5-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-dodecahydro-2H-spiro[oxolane-3,1-phenanthrene]-2-yl)-1-(4-methyl-5-oxo-2,5-dihydrofuran-2-yl)butan-2-yl acetate

C38H58O12 (706.3928)


   

Cimimanol A

24S,25-carbonyl-23R,acetoxy-3beta,15alpha,24R,25-tetrahydroxy-cyclo-lanostan-16one-3- O-beta-D-xylopyranoside

C38H58O12 (706.3928)


   

Ruscoponticoside C

Ruscoponticoside C

C38H58O12 (706.3928)


   

PA(i-12:0/TXB2)

PA(i-12:0/TXB2)

C35H63O12P (706.4057)


   

PA(TXB2/i-12:0)

PA(TXB2/i-12:0)

C35H63O12P (706.4057)


   

PA(12:0/6 keto-PGF1alpha)

PA(12:0/6 keto-PGF1alpha)

C35H63O12P (706.4057)


   

PA(6 keto-PGF1alpha/12:0)

PA(6 keto-PGF1alpha/12:0)

C35H63O12P (706.4057)


   
   
   

PA(i-12:0/6 keto-PGF1alpha)

PA(i-12:0/6 keto-PGF1alpha)

C35H63O12P (706.4057)


   

PA(6 keto-PGF1alpha/i-12:0)

PA(6 keto-PGF1alpha/i-12:0)

C35H63O12P (706.4057)


   

(2S,3R,4R,5R,6S)-2-[(2S,3R,4S,5S)-4,5-dihydroxy-2-[(1S,4S,6R,7S,8R,9S,13R,14R,16S)-14-hydroxy-7,9,13-trimethyl-5-methylidenespiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2-oxane]-16-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol

(2S,3R,4R,5R,6S)-2-[(2S,3R,4S,5S)-4,5-dihydroxy-2-[(1S,4S,6R,7S,8R,9S,13R,14R,16S)-14-hydroxy-7,9,13-trimethyl-5-methylidenespiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2-oxane]-16-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol

C38H58O12 (706.3928)


   

Smgdg O-24:3_2:0

Smgdg O-24:3_2:0

C35H62O12S (706.3962)


   

Smgdg O-8:0_18:3

Smgdg O-8:0_18:3

C35H62O12S (706.3962)


   

Smgdg O-22:3_4:0

Smgdg O-22:3_4:0

C35H62O12S (706.3962)


   

Smgdg O-18:3_8:0

Smgdg O-18:3_8:0

C35H62O12S (706.3962)


   

Smgdg O-20:3_6:0

Smgdg O-20:3_6:0

C35H62O12S (706.3962)


   

Smgdg O-10:0_16:3

Smgdg O-10:0_16:3

C35H62O12S (706.3962)


   

Smgdg O-16:3_10:0

Smgdg O-16:3_10:0

C35H62O12S (706.3962)


   

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

C35H63O12P (706.4057)


   

[1-decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C35H63O12P (706.4057)


   

[6-[2,3-bis[[(Z)-tridec-9-enoyl]oxy]propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[6-[2,3-bis[[(Z)-tridec-9-enoyl]oxy]propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H62O12S (706.3962)


   

[(2S,3S,6S)-6-[3-decanoyloxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

[(2S,3S,6S)-6-[3-decanoyloxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid

C35H62O12S (706.3962)


   
   
   
   
   

PG P-18:0/11:3;O3

PG P-18:0/11:3;O3

C35H63O12P (706.4057)


   

PG 16:0/13:3;O2

PG 16:0/13:3;O2

C35H63O12P (706.4057)


   
   
   
   
   
   
   
   
   

PI P-22:1/4:1 or PI O-22:2/4:1

PI P-22:1/4:1 or PI O-22:2/4:1

C35H63O12P (706.4057)


   
   

PI P-26:2 or PI O-26:3

PI P-26:2 or PI O-26:3

C35H63O12P (706.4057)


   

(2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(carboxymethoxy)carbonyl]-8-hydroxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

(2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(carboxymethoxy)carbonyl]-8-hydroxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C38H58O12 (706.3928)


   

4-({6-ethyl-2-hydroxy-2-[3-hydroxy-4-(10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl)pentan-2-yl]-5-methyloxan-4-yl}oxy)-4-oxobut-2-enoic acid

4-({6-ethyl-2-hydroxy-2-[3-hydroxy-4-(10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl)pentan-2-yl]-5-methyloxan-4-yl}oxy)-4-oxobut-2-enoic acid

C38H58O12 (706.3928)


   

3-{[(2s,3r,4s,5r)-2-{[(1s,2r,5s,7s,10r,12s,15r,16r,17s,18r,21r,22r,24s)-21,22-dihydroxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl]oxy}-4,5-dihydroxyoxan-3-yl]oxy}-3-oxopropanoic acid

3-{[(2s,3r,4s,5r)-2-{[(1s,2r,5s,7s,10r,12s,15r,16r,17s,18r,21r,22r,24s)-21,22-dihydroxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl]oxy}-4,5-dihydroxyoxan-3-yl]oxy}-3-oxopropanoic acid

C38H58O12 (706.3928)


   

3-{[2-({21,22-dihydroxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl}oxy)-4,5-dihydroxyoxan-3-yl]oxy}-3-oxopropanoic acid

3-{[2-({21,22-dihydroxy-1,6,6,15,17,20,20-heptamethyl-19,23-dioxaheptacyclo[13.10.0.0²,¹².0⁵,¹⁰.0¹⁰,¹².0¹⁶,²⁴.0¹⁸,²²]pentacosan-7-yl}oxy)-4,5-dihydroxyoxan-3-yl]oxy}-3-oxopropanoic acid

C38H58O12 (706.3928)


   

4-{6-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-4,9,10,13-tetramethyl-17-oxotetracyclo[11.3.1.0¹,¹⁰.0⁴,⁹]heptadecan-14-yl}-5h-furan-2-one

4-{6-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-4,9,10,13-tetramethyl-17-oxotetracyclo[11.3.1.0¹,¹⁰.0⁴,⁹]heptadecan-14-yl}-5h-furan-2-one

C38H58O12 (706.3928)


   

(2e)-4-{[(2r,4r,5r,6r)-6-ethyl-2-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(3s,4z,6z,9s,10s,11r,12z,14e)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-5-methyloxan-4-yl]oxy}-4-oxobut-2-enoic acid

(2e)-4-{[(2r,4r,5r,6r)-6-ethyl-2-hydroxy-2-[(2s,3r,4s)-3-hydroxy-4-[(3s,4z,6z,9s,10s,11r,12z,14e)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-5-methyloxan-4-yl]oxy}-4-oxobut-2-enoic acid

C38H58O12 (706.3928)


   

(2e)-4-{[(2r,4r,5r,6r)-2-[(2s,3r,4s)-3-hydroxy-4-[(2r,3s,4z,6z,9s,10s,11r,12z,14e)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-2-methoxy-5,6-dimethyloxan-4-yl]oxy}-4-oxobut-2-enoic acid

(2e)-4-{[(2r,4r,5r,6r)-2-[(2s,3r,4s)-3-hydroxy-4-[(2r,3s,4z,6z,9s,10s,11r,12z,14e)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]pentan-2-yl]-2-methoxy-5,6-dimethyloxan-4-yl]oxy}-4-oxobut-2-enoic acid

C38H58O12 (706.3928)


   

(2s,3s,4as,5r,8as)-5-[(3s)-5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[(2s,3r,4s,5r)-3,4,5-tris(acetyloxy)oxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl (2z)-2-methylbut-2-enoate

(2s,3s,4as,5r,8as)-5-[(3s)-5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[(2s,3r,4s,5r)-3,4,5-tris(acetyloxy)oxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl (2z)-2-methylbut-2-enoate

C38H58O12 (706.3928)


   

(2s,3r)-3-[(2'r,3s,4'ar,4'br,7's,8'as,10'ar)-4'b,8',8',10'a-tetramethyl-5-oxo-7'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrospiro[oxolane-3,1'-phenanthren]-2'-yl]-1-[(2r)-4-methyl-5-oxo-2h-furan-2-yl]butan-2-yl acetate

(2s,3r)-3-[(2'r,3s,4'ar,4'br,7's,8'as,10'ar)-4'b,8',8',10'a-tetramethyl-5-oxo-7'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrospiro[oxolane-3,1'-phenanthren]-2'-yl]-1-[(2r)-4-methyl-5-oxo-2h-furan-2-yl]butan-2-yl acetate

C38H58O12 (706.3928)


   

(1s,2r,5r,7r,8r,10s,11s,19s,22r)-22-hydroxy-10-(hydroxymethyl)-1,2,6,6,19-pentamethyl-16-oxo-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

(1s,2r,5r,7r,8r,10s,11s,19s,22r)-22-hydroxy-10-(hydroxymethyl)-1,2,6,6,19-pentamethyl-16-oxo-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

C38H58O12 (706.3928)


   

3-(4'b,8',8',10'a-tetramethyl-5-oxo-7'-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrospiro[oxolane-3,1'-phenanthren]-2'-yl)-1-(4-methyl-5-oxo-2h-furan-2-yl)butan-2-yl acetate

3-(4'b,8',8',10'a-tetramethyl-5-oxo-7'-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrospiro[oxolane-3,1'-phenanthren]-2'-yl)-1-(4-methyl-5-oxo-2h-furan-2-yl)butan-2-yl acetate

C38H58O12 (706.3928)


   

2-[(4,5-dihydroxy-2-{7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy}oxan-3-yl)oxy]-6-methyloxane-3,4,5-triol

2-[(4,5-dihydroxy-2-{7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy}oxan-3-yl)oxy]-6-methyloxane-3,4,5-triol

C38H58O12 (706.3928)


   

(2s,3r)-3-[(2'r,3s,4'ar,4'br,7's,8'ar,10'ar)-4'b,8',8',10'a-tetramethyl-5-oxo-7'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrospiro[oxolane-3,1'-phenanthren]-2'-yl]-1-[(2r)-4-methyl-5-oxo-2h-furan-2-yl]butan-2-yl acetate

(2s,3r)-3-[(2'r,3s,4'ar,4'br,7's,8'ar,10'ar)-4'b,8',8',10'a-tetramethyl-5-oxo-7'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrospiro[oxolane-3,1'-phenanthren]-2'-yl]-1-[(2r)-4-methyl-5-oxo-2h-furan-2-yl]butan-2-yl acetate

C38H58O12 (706.3928)


   

4-[(1r,4s,6s,9s,10r,13r,14r)-6-{[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4,9,10,13-tetramethyl-17-oxotetracyclo[11.3.1.0¹,¹⁰.0⁴,⁹]heptadecan-14-yl]-5h-furan-2-one

4-[(1r,4s,6s,9s,10r,13r,14r)-6-{[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4,9,10,13-tetramethyl-17-oxotetracyclo[11.3.1.0¹,¹⁰.0⁴,⁹]heptadecan-14-yl]-5h-furan-2-one

C38H58O12 (706.3928)


   

(2s,3r,4r,5r,6s)-2-{[(2s,3r,4s,5s)-4,5-dihydroxy-2-[(1's,2r,2's,4's,7's,8'r,9's,12's,13'r,14'r,16'r)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

(2s,3r,4r,5r,6s)-2-{[(2s,3r,4s,5s)-4,5-dihydroxy-2-[(1's,2r,2's,4's,7's,8'r,9's,12's,13'r,14'r,16'r)-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-16'-oloxy]oxan-3-yl]oxy}-6-methyloxane-3,4,5-triol

C38H58O12 (706.3928)


   

(1r,2s,5r,7r,8r,10s,11s,18s,19r,22s,23r)-22-hydroxy-10-(hydroxymethyl)-1,2,6,6,19-pentamethyl-16-oxo-7-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

(1r,2s,5r,7r,8r,10s,11s,18s,19r,22s,23r)-22-hydroxy-10-(hydroxymethyl)-1,2,6,6,19-pentamethyl-16-oxo-7-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

C38H58O12 (706.3928)


   

5-[5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[3,4,5-tris(acetyloxy)oxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl 2-methylbut-2-enoate

5-[5-(acetyloxy)-3-methylpentyl]-1,1,4a,6-tetramethyl-3-{[3,4,5-tris(acetyloxy)oxan-2-yl]oxy}-2,3,4,5,8,8a-hexahydronaphthalen-2-yl 2-methylbut-2-enoate

C38H58O12 (706.3928)


   

22-hydroxy-10-(hydroxymethyl)-1,2,6,6,19-pentamethyl-16-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

22-hydroxy-10-(hydroxymethyl)-1,2,6,6,19-pentamethyl-16-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

C38H58O12 (706.3928)